Overview

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

Status:
RECRUITING
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grad lymphomas.
Phase:
PHASE1
Details
Lead Sponsor:
Eilean Therapeutics